Cancer preventive agents 10. Prenylated dehydrozingerone analogs as potent chemopreventive agents.
Dehydrozingerone analogs and related compounds were screened as potential antitumor promoters by using the in vitro short-term 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein-Barr virus early antigen activation assay. Among the 40 synthesized compounds, the prenylated analogs 16 and 34-36 showed the most significant and promising activity (100% inhibition of activation at 1 x 10(3) mol ratio/TPA, and 82-80%, 37-35%, and 13-11% inhibition at 5 x 10(2), 1 x 10(2), and 1 x 10 mol ratio/TPA, respectively) in this screening. Their activity profiles were comparable to those of the reference standard curcumin. While a prenyl moiety conferred potent chemopreventive activity, an extended prenyl unit such as a farnesyl moiety did not improve activity. Because in vitro inhibitory effects in this assay generally correlate well with in vivo inhibitory effects on tumor promotion, our results strongly suggested that prenylated 16 and 34-36 are likely to be promising antitumor promoters.
Tatsuzaki
Jin
J
Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Nakagawa-Goto
Kyoko
K
Tokuda
Harukuni
H
Lee
Kuo-Hsiung
KH
D016588:Anticarcinogenic Agents / Q000737:chemistry* / Q000494:pharmacology*; D000956:Antigens, Viral / Q000187:drug effects*; D002273:Carcinogens / Q000494:pharmacology; D020650:Combinatorial Chemistry Techniques; D003474:Curcumin / Q000494:pharmacology; D015394:Molecular Structure; D013237:Stereoisomerism; D013343:Styrenes / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D000956:Antigens, Viral; D002273:Carcinogens; C033305:Epstein-Barr virus early antigen; D013343:Styrenes; C052933:methyl-3-methoxy-4-hydroxystyryl ketone; D003474:Curcumin; D013755:Tetradecanoylphorbol Acetate
J Bacteriol. 1966 Mar;91(3):1248-56
4160230
Bioorg Med Chem. 2003 Mar 20;11(6):1137-40
12614901
Chem Pharm Bull (Tokyo). 1990 Oct;38(10):2737-9
1963812
Bioorg Med Chem. 2002 Oct;10(10):3361-5
12150883
Biol Pharm Bull. 1994 May;17(5):668-71
7920430
J Nat Prod. 2003 Feb;66(2):200-5
12608849
J Nat Prod. 2000 Oct;63(10):1344-8
11076549
Cancer Lett. 2004 Oct 28;214(2):165-9
15363542
J Nat Prod. 2004 Jul;67(7):1125-30
15270565
Cancer Lett. 1999 Jul 19;142(1):49-54
10424780
Cancer Lett. 2003 Nov 25;201(2):133-7
14607326
Cancer Lett. 2000 Oct 31;159(2):135-40
10996724
Cancer Lett. 1995 Jul 20;94(1):79-83
7621448
Cancer Lett. 2003 Apr 25;193(2):133-8
12706869
Cancer Lett. 1986 Dec;33(3):279-85
3802058
Cancer Res. 1988 Nov 1;48(21):5941-6
3139287
J Nat Prod. 2003 Feb;66(2):206-9
12608850
Biochem Pharmacol. 1996 Aug 23;52(4):519-25
8759023
Cancer Lett. 1998 Dec 11;134(1):37-42
10381128
J Nat Prod. 2006 Oct;69(10):1445-9
17067159